CP3 Director Dr. Walid Gellad has been carefully following the President's COVID-19 diagnosis and treatment, and ne's been highlighting what we should know about each clinical decision. Time and Reuters have included his observations with those from other clinicians. As Dr. Gellad told Time, "It’s a little unprecedented that anyone so early [in their disease] would be receiving [remdesivir]."